Wright Investors Service Inc. Purchases 118 Shares of Amgen, Inc. (NASDAQ:AMGN)

Wright Investors Service Inc. grew its position in Amgen, Inc. (NASDAQ:AMGN) by 0.6% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 18,582 shares of the medical research company’s stock after acquiring an additional 118 shares during the quarter. Amgen accounts for 1.3% of Wright Investors Service Inc.’s portfolio, making the stock its 20th biggest holding. Wright Investors Service Inc.’s holdings in Amgen were worth $3,424,000 at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in AMGN. Kavar Capital Partners LLC bought a new position in shares of Amgen during the 2nd quarter valued at approximately $81,000. Executive Wealth Management LLC increased its position in shares of Amgen by 12.4% during the 2nd quarter. Executive Wealth Management LLC now owns 6,815 shares of the medical research company’s stock valued at $1,256,000 after purchasing an additional 754 shares during the last quarter. Stephens Inc. AR increased its position in shares of Amgen by 11.0% during the 2nd quarter. Stephens Inc. AR now owns 37,892 shares of the medical research company’s stock valued at $6,983,000 after purchasing an additional 3,740 shares during the last quarter. TRUE Private Wealth Advisors increased its position in shares of Amgen by 3.9% during the 2nd quarter. TRUE Private Wealth Advisors now owns 3,772 shares of the medical research company’s stock valued at $695,000 after purchasing an additional 140 shares during the last quarter. Finally, Jacobs & Co. CA increased its position in shares of Amgen by 0.6% during the 2nd quarter. Jacobs & Co. CA now owns 39,419 shares of the medical research company’s stock valued at $7,264,000 after purchasing an additional 234 shares during the last quarter. 78.96% of the stock is currently owned by institutional investors and hedge funds.

In other Amgen news, Director Ronald D. Sugar sold 2,000 shares of the company’s stock in a transaction on Wednesday, July 3rd. The stock was sold at an average price of $187.58, for a total value of $375,160.00. Following the completion of the sale, the director now directly owns 16,336 shares in the company, valued at approximately $3,064,306.88. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director R Sanders Williams sold 425 shares of the company’s stock in a transaction on Wednesday, August 7th. The stock was sold at an average price of $183.04, for a total value of $77,792.00. Following the completion of the sale, the director now owns 16,336 shares of the company’s stock, valued at $2,990,141.44. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 4,425 shares of company stock valued at $804,312. 0.25% of the stock is owned by company insiders.

Several equities analysts have recently weighed in on AMGN shares. BidaskClub raised Amgen from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st. Piper Jaffray Companies set a $210.00 target price on Amgen and gave the company a “buy” rating in a research report on Saturday, August 10th. Credit Suisse Group set a $202.00 target price on Amgen and gave the company a “buy” rating in a research report on Monday. Royal Bank of Canada reissued a “hold” rating on shares of Amgen in a research report on Sunday. Finally, Wells Fargo & Co boosted their target price on Amgen from $197.00 to $202.00 and gave the company a “market perform” rating in a research report on Monday. Nine research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $211.44.

AMGN traded up $1.65 during trading hours on Thursday, reaching $200.52. 107,461 shares of the company’s stock traded hands, compared to its average volume of 3,546,323. The company’s 50-day moving average price is $183.21. Amgen, Inc. has a 52-week low of $166.30 and a 52-week high of $211.90. The company has a debt-to-equity ratio of 2.58, a current ratio of 2.89 and a quick ratio of 2.60. The firm has a market capitalization of $119.83 billion, a price-to-earnings ratio of 13.94, a PEG ratio of 2.42 and a beta of 1.19.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Tuesday, July 30th. The medical research company reported $3.97 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $3.58 by $0.39. Amgen had a return on equity of 76.17% and a net margin of 33.78%. The company had revenue of $5.87 billion during the quarter, compared to analysts’ expectations of $5.67 billion. During the same quarter in the previous year, the business earned $3.83 EPS. Amgen’s revenue was down 3.1% compared to the same quarter last year. Sell-side analysts forecast that Amgen, Inc. will post 14.25 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, September 6th. Investors of record on Thursday, August 15th will be issued a dividend of $1.45 per share. This represents a $5.80 dividend on an annualized basis and a yield of 2.89%. The ex-dividend date of this dividend is Wednesday, August 14th. Amgen’s payout ratio is currently 40.28%.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.

Featured Story: What is Compound Interest?

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.